Article Text

Download PDFPDF
Cochrane corner: implantable cardiac defibrillators for patients with non-ischaemic cardiomyopathy
  1. Mohamad El Moheb,
  2. Johny Nicolas,
  3. Assem Khamis,
  4. Elie A Akl,
  5. Marwan M Refaat
  1. Faculty of Medicine, American University of Beirut, Beirut, Lebanon
  1. Correspondence to Dr Marwan M Refaat, American University of Beirut Faculty of Medicine, Beirut 1107 2020, Lebanon; mr48{at}

Statistics from


The addition of implantable cardioverter defibrillators (ICDs) to standard medical therapy has been shown to decrease mortality in patients with ischaemic cardiomyopathy with a low ejection fraction (LVEF).1 In contrast, studies investigating the use of ICDs in dilated non-ischaemic cardiomyopathy showed conflicting results. The Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) study showed a decrease in mortality rate, while the Cardiomyopathy Trial (CAT) and Amiodarone Versus Implantable Defibrillator (AMIOVIRT) trial did not find any difference between the intervention and control groups.2–4 The results of a 2016 large randomised controlled trial (RCT) (the Danish Study to Assess the Efficacy of ICDs in Patients with Non-ischemic Systolic Heart Failure on Mortality (DANISH)) showed that the use of ICDs in dilated non-ischaemic cardiomyopathy does not decrease all-cause mortality, challenging the recommendations of the American College of Cardiology and the European Society of Cardiology guidelines.3

Several systematic reviews have addressed this topic since the publication of the DANISH trial; however, none of them used the Cochrane methodology nor studied the cost-effectiveness of ICD therapy and its impact on adverse events and quality of life. We therefore conducted a Cochrane systematic review to assess the benefits and harms of using versus not using ICD in addition to medical therapy in patients with dilated non-ischaemic cardiomyopathy.4 A Permission toco-publish an abridged version of a Cochrane Review in Heart was obtained (online supplementary appendix 1). We also studied the effect of ICDs on adverse events and quality of life, and the cost-effectiveness of this intervention. We reported and analysed …

View Full Text


  • Twitter @assemmkhamis, @DrMarwanRefaat

  • Correction notice Since this article was first published online, the middle intial A has been added to the author name Elie Akl.

  • Contributors All authors contributed to the manuscript.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Disclaimer This review is an abridged version of a Cochrane Review previously published in the Cochrane Database of Systematic Reviews 2018, Issue 12, DOI: 10.1002/14651858.CD0012738 (see for information). Cochrane Reviews are regularly updated as new evidence emerges and in response to feedback, and Cochrane Database of Systematic Reviews should be consulted for the most recent version of the review.

  • Competing interests None declared.

  • Patient consent for publication Not required.

  • Provenance and peer review Commissioned; internally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.